{
Jo Walton

People

}
Very Negative
Negative
Neutral
Positive
Very Positive
2025-03-282025-03-281133221100
Download SVG
Download PNG
Download CSV
Somewhat Relevant
Moderately Relevant
Very Relevant
Highly Relevant
2025-03-282025-03-28233221100
Download SVG
Download PNG
Download CSV

ubs predicts over 50 percent recovery for novo nordisk shares

Novo Nordisk's shares have dropped over 20% this year, primarily due to disappointing results for its weight loss drug CagriSema and concerns about Wegovy's market performance against Eli Lilly's Zepbound. Despite this, UBS maintains a "buy" rating with a target price of 750 DKK, suggesting a potential 56% upside. Wall Street remains divided, with half of analysts recommending a buy and the other half advising to hold, but no sell ratings are present.
@aktionaer
Danish Krone Morgan Stanley Novo Nordisk A/S Eli Lilly and Co DNK Jo Walton Eli Lilly Show more
Finance & Economy, Market Report
19:30 28.03.2025

ubs maintains buy rating for novo nordisk with target price of 750 crowns

UBS has maintained its "Buy" rating for Novo Nordisk, setting a target price of 750 Danish crowns, influenced by current trends in weight loss drugs, particularly GLP-1. Analyst Jo Walton noted growth for Eli Lilly's Zepbound, while other competitors are seeing declines.
boerse.de
Danish Krone Novo Nordisk A/S Eli Lilly and Co DNK Jo Walton
Finance & Economy, Market Report
16:06 28.03.2025

ubs maintains buy rating for novo nordisk despite disappointing wegovy growth

UBS has maintained its "Buy" rating for Novo Nordisk, setting a target price of 750 Danish crowns. Analyst Jo Walton noted disappointing growth in the US for the GLP-1 weight loss drug Wegovy in the first quarter, indicating that promotional efforts may not have been effective and that the company has lost market share among new patients.
finanzen.ch
Danish Krone United States Dollar Novo Nordisk A/S UBS AG DNK Jo Walton
Business & Industry, Market Report
18:16 21.03.2025

ubs maintains buy rating for novo nordisk with price target of 750 dkk

UBS has maintained a "Buy" rating for Novo Nordisk, setting a price target of 750 Danish kroner. Analyst Jo Walton noted disappointing growth trends for the GLP-1 weight loss drug Wegovy in the U.S. market during the first quarter, attributing it to ineffective marketing efforts and a loss of market share among new patients.
boerse.de
Novo Nordisk A/S DNK Jo Walton
Finance & Economy, Market Report
17:03 21.03.2025

ubs maintains buy rating on novo nordisk despite declining wegovy prescriptions

UBS has maintained a "Buy" rating on Novo Nordisk, setting a target price of 750 Danish kroner. Recent data indicates a decline in initial prescription trends for the company's GLP-1 weight loss drug, Wegovy, in the US market as of March 7, according to analyst Jo Walton.
finanzen.ch
Danish Krone Swiss Franc Novo Nordisk A/S DNK Jo Walton
Finance & Economy, Market Report
23:34 17.03.2025

ubs maintains buy rating for novo nordisk with target price of 750 crowns

UBS has maintained a "Buy" rating on Novo Nordisk with a target price of 750 Danish crowns. Recent data indicated a decline in initial prescription trends for Wegovy, the company's GLP-1 weight loss drug, in the US market for the week ending March 7, according to analyst Jo Walton.
boerse.de
Danish Krone Novo Nordisk A/S DNK Jo Walton
Finance & Economy, Market Report
21:07 17.03.2025

UBS maintains neutral rating on Bayer amid potential share issue

UBS has maintained a "Neutral" rating for Bayer with a target price of 22 euros, citing a potential new share issue as a step towards resolving legal disputes in the U.S. Analyst Jo Walton noted that this action may not be necessary if Bayer's legislative efforts succeed or if the U.S. Supreme Court intervenes.
boerse.de
Euro DEU Jo Walton
Finance & Economy, Market Report
18:59 07.03.2025

UBS maintains buy rating for Novo Nordisk with target price of 750 crowns

UBS has maintained its "Buy" rating for Novo Nordisk, setting a target price of 750 Danish crowns. Analyst Jo Walton noted a strong recovery in the prescription trend for GLP-1 weight loss drugs, marking the best figures of the year, though she refrained from declaring a definitive trend reversal.
boerse.de
Danish Krone Novo Nordisk A/S DNK Jo Walton
Finance & Economy, Market Report
14:48 07.03.2025

UBS maintains neutral rating for Bayer with price target of 22 euros

UBS has maintained a "Neutral" rating for Bayer, setting a price target of 22 euros. Analyst Jo Walton noted that Bayer's 2024 business figures met adjusted market expectations, with slight improvements in the pharmaceuticals sector and operating free cash flow, though the forecast for lower free cash flow this year was disappointing.
boerse.de
Euro DEU Thomas Müller Jo Walton Warren Buffett Hubert Dichtl Show more
Business & Industry, Market Report
09:04 06.03.2025

ubs maintains buy rating for novo nordisk with target price of 750 kroner

UBS has maintained a 'Buy' rating for Novo Nordisk, setting a target price of 750 Danish crowns. Despite this, the company has recently underperformed compared to Eli Lilly in the initial prescriptions of GLP-1 class weight loss drugs, leading to a slightly disappointing overall development.
MarketScreener
Danish Krone Novo Nordisk A/S DNK Jo Walton
Finance & Economy, Market Report
17:05 03.03.2025
Trending
Subcategory
Stock Market Updates Corporate News Industry Trends Finance Mergers & Acquisitions Banking Regulations Global Financial Events Market Analysis and Predictions Financial Scams and Security Retail and Consumer Goods CEO Changes Central Bank Actions Industry Mergers & Acquisitions Hedge Funds & Private Equity Global Trade Developments Government Policies GDP Growth & Recession Forecasts Workplace Trends Inflation and Monetary Impact Startups & Entrepreneurship Government Economic Policies
Countries:
USA CHN GBR FRA DEU CHE IND CAN JPN ITA RUS AUS ARE SAU KOR MEX ESP ARG IRL BEL
Companies:
JPMorgan Chase & Co. The Goldman Sachs Group, Inc. Tesla, Inc. Bank of America Corporation Apple Inc. Citigroup Inc. Wells Fargo & Company Barclays PLC Morgan Stanley Lloyds Banking Group plc Huawei Technologies CO. Ltd. Deutsche Bank Money Market PP American Express Company UBS Group AG AMERICAN EXPRESS Northern Trust Corporation Berkshire Hathaway Inc. Credit Suisse Strategic Income I AXA SA Safran SA
Currencies:
United States Dollar Euro Chinese Yuan Swiss Franc British Pound Sterling Indian Rupee Japanese Yen Canadian Dollar Russian Ruble Australian Dollar Saudi Riyal United Arab Emirates Dirham Indonesian Rupiah Offshore Chinese Yuan Singapore Dollar Ghanaian Cedi Mexican Peso Hong Kong Dollar South Korean Won Danish Krone
People:
Donald Trump Elon Musk Michael J. Angelakis Troy L Rohrbaugh Charlie Javice Goldman Sachs Warren Buffett Sara Wechter Brad Schimel Olivier Amar Robin Leopold Jennifer Piepszak Anand Selvakesari Mark Mason Susan P. Crawford Will Hardcastle Karin Keller-Sutter Jerome Powell Stacey Friedman Raja Akram

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Links

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Reset settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.